AU2022223224A1 - Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia - Google Patents

Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia Download PDF

Info

Publication number
AU2022223224A1
AU2022223224A1 AU2022223224A AU2022223224A AU2022223224A1 AU 2022223224 A1 AU2022223224 A1 AU 2022223224A1 AU 2022223224 A AU2022223224 A AU 2022223224A AU 2022223224 A AU2022223224 A AU 2022223224A AU 2022223224 A1 AU2022223224 A1 AU 2022223224A1
Authority
AU
Australia
Prior art keywords
obicetrapib
ezetimibe
combination
previous
ldl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022223224A
Other languages
English (en)
Inventor
Michael Harvey Davidson
Marc DITMARSCH
Johannes Jacob Pieter KASTELEIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NewAmsterdam Pharma NV
Original Assignee
NewAmsterdam Pharma NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NewAmsterdam Pharma NV filed Critical NewAmsterdam Pharma NV
Publication of AU2022223224A1 publication Critical patent/AU2022223224A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2022223224A 2021-02-18 2022-02-18 Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia Pending AU2022223224A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2021050109 2021-02-18
NLPCT/NL2021/050109 2021-02-18
PCT/NL2022/050083 WO2022177428A1 (en) 2021-02-18 2022-02-18 Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia

Publications (1)

Publication Number Publication Date
AU2022223224A1 true AU2022223224A1 (en) 2023-08-24

Family

ID=74844966

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022223224A Pending AU2022223224A1 (en) 2021-02-18 2022-02-18 Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia

Country Status (11)

Country Link
US (1) US20240189311A1 (https=)
EP (1) EP4294387A1 (https=)
JP (1) JP2024507810A (https=)
KR (1) KR20230159380A (https=)
CN (1) CN117042770A (https=)
AU (1) AU2022223224A1 (https=)
BR (1) BR112023016682A2 (https=)
CA (1) CA3210033A1 (https=)
IL (1) IL304544A (https=)
MX (1) MX2023009613A (https=)
WO (1) WO2022177428A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025146445A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Pharmaceutical compositions of obicetrapib and ezetimibe
WO2025147235A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Fixed dose combination composition of obicetrapib and ezetimibe

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12006305B2 (en) 2022-07-05 2024-06-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
WO2024165395A1 (en) * 2023-02-07 2024-08-15 Newamsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions
WO2025146262A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Obicetrapib for use in the treatment of hemoglobinopathies
WO2025146446A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Pharmaceutical compositions of obicetrapib

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
MX369471B (es) * 2014-02-05 2019-11-08 Dezima Pharma B V Inhibidor de proteina de transferencia del ester de colesterilo (cetp) y composiciones farmaceuticas que comprenden el inhibidor para uso en el tratamiento o prevencion de enfermedades cardiovasculares.
WO2017023166A1 (en) * 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and a cholesterol absorption inhibitor
US12006305B2 (en) * 2022-07-05 2024-06-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
JP2025527686A (ja) * 2022-08-22 2025-08-22 ニューアムステルダム・ファルマ・ベー・フェー オビセトラピブ及びエゼチミブ併用治療及び固定用量医薬組成物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025146445A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Pharmaceutical compositions of obicetrapib and ezetimibe
WO2025147235A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Fixed dose combination composition of obicetrapib and ezetimibe

Also Published As

Publication number Publication date
JP2024507810A (ja) 2024-02-21
CN117042770A (zh) 2023-11-10
IL304544A (en) 2023-09-01
MX2023009613A (es) 2023-11-09
WO2022177428A1 (en) 2022-08-25
BR112023016682A2 (pt) 2023-11-14
EP4294387A1 (en) 2023-12-27
KR20230159380A (ko) 2023-11-21
US20240189311A1 (en) 2024-06-13
CA3210033A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
US20240189311A1 (en) Combination Therapy of Obicetrapib and Ezetimibe for Use in Statin Intolerant Patients Suffering from Hyperlipidemia or Mixed Dyslipidaemia
US20220152052A1 (en) Methods and compositions for treating various disorders
US6511985B1 (en) Combination of cerivastatin and fibrates
JP7304913B2 (ja) コレステリルエステル転送タンパク質阻害剤及びＨＭＧ ＣｏＡ還元酵素阻害剤を含む医薬組成物及び治療併用剤
ES2276774T3 (es) Nueva combinacion de betabloqueante y un agente hipocolesterolemiante.
AU2021388141A9 (en) Treatment of raynaud's disease
JP4901218B2 (ja) 併用医薬
US20070275996A1 (en) Use of Statins For The Treatment Of Metabolic Syndrome
JP2024532129A5 (https=)
CN1437484A (zh) 含有β－受体阻滞剂和任选的降胆固醇剂的新型制剂
JPH09227371A (ja) 粥状動脈硬化抑制剤
JPWO2005107746A1 (ja) 脂質代謝異常の予防または治療用医薬組成物
HK1051325B (en) New combination of a betablocker and a cholesterol-lowering agent